Journal of the American Medical Association | January 13, 2023Read the Publication
In 2022, several bills were introduced in Congress to revamp US intellectual property law. Although these bills did not receive a full vote in the turmoil of the previous election year, they show momentum gathering among legislators to introduce intellectual property reforms in the name of promoting innovation. Three bills, focused on patent eligibility, fraud, and quality, have major implications for clinical medicine and pharmaceutical development. Because all 3 bills will likely be reintroduced, we analyzed their implications for patients and clinicians.